GlassScriptPhysician profile
Moogali M Arvind
NPI 1730193665
$16,047.49
in general payments reported to CMS, 2019-2025
60 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,290 · 2020: $1,234 · 2021: $3,006 · 2022: $2,892 · 2023: $2,190 · 2024: $2,527 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,625.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,119.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,842.48 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,487.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,206.81 | 2019-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,097.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,027.14 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $859.64 | 2019-2025 | Belbuca, Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $646.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $544.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $491.01 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Daiichi Sankyo INC. | $471.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.66 | 2019-2025 | Jardiance |
| Abbott Laboratories | $252.93 | 2021-2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $230.86 | 2021-2022 | |
| Amarin Pharma, INC. | $230.59 | 2019-2021 |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moogali Arvind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.